Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China To Produce Generic Anti-Hepatitis B Virus Drug Entecavir

This article was originally published in PharmAsia News

Executive Summary

Hainan Zhonghe Pharmaceutical has obtained clinical trial approval for entecavir tablets, marking China's capability to produce a first-line drug for chronic hepatitis B treatment. Locally made entecavir, expected to be marketed in 2010, will provide patients with a lower-priced option. Baraclude, the imported entecavir marketed in the country by Sino-American Shanghai Squibb Pharmaceuticals since 2006, has been enjoying brisk sales. However, the new generic entecavir will likely impact Baraclude sales and possibly even restructure the domestic anti-hepatitis B drug market. (Click here for more - Chinese Language)

You may also be interested in...



Specialists Advocate Helmet Ventilation For COVID-19 Hospital Treatment

Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.

 

Global Medtech Guidance Tracker: March 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.

AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies

The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.

UsernamePublicRestriction

Register

SC071839

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel